University Of Pittsburgh Medical Center Researchers Present Preliminary Evidence Demonstrating Gene Expression In World's First Arthritis Gene Therapy

February 11, 1997

SAN FRANCISCO, Feb. 11 -- Results of several tests indicate the successful transfer and expression of a therapeutic gene in the world's first arthritis gene therapy patient, according to a presentation today by a research team from the University of Pittsburgh Medical Center (UPMC) at the annual meeting of the American Academy of Orthopaedic Surgeons in San Francisco. "Our results indicate that we can successfully detect expression of the gene within one week of delivering genetically modified cells to a patient with rheumatoid arthritis," said Richard Kang, M.D., presenter of the research findings, a co-investigator on the study and a resident in the UPMC's department of orthopaedic surgery.

"We are hopeful that this is the first in a series of treated patients who express the gene, underscoring the potential utility of this approach in treating rheumatoid arthritis," said Chris Evans, Ph.D., principal investigator for the study, director of the Ferguson Laboratory for Orthopaedic Research and Henry J. Mankin Professor of Orthopaedic Surgery.

This early-phase study is evaluating the use of a gene for an anti-arthritic protein in patients with rheumatoid arthritis (RA), a common, crippling disease for which there is no cure and few useful treatments. This study is the first to explore gene therapy for an autoimmune disease and marks the transition of gene therapy investigations from their use in fatal diseases such as AIDS or cancer to chronic disorders.

UPMC researchers designed the arthritis gene therapy trial because delivering anti-arthritic proteins to patients with RA is difficult. "We theorized that after we delivered the genes that encode anti-arthritic proteins to a patient's joint, that joint could locally produce its own medicine," said Paul Robbins, Ph.D., associate professor of molecular genetics and biochemistry and co-principal investigator on the study.

Drs. Evans and Robbins first demonstrated the feasibility of this approach in rabbits with arthritis. In this model, a gene for an anti-arthritic protein was successfully transferred and expressed. Moreover, they found that rabbits benefitted therapeutically.

The investigators focused on the gene for interleukin-1 receptor antagonist (IL-1Ra), a safe, naturally occurring protein that blocks the actions of another protein, interleukin-1 (IL-1), which is involved in the production of joint inflammation and destruction associated with arthritis.

The first patient's tissues have undergone several qualitative analyses, including polymerase chain reaction, which indicated that the introduced genetic material, or DNA, was transcribed into RNA, the template from which the IL1-Ra protein is made. Researchers also performed in situ hybridization, which detects IL1-Ra RNA in the tissues. They discovered that the gene was successfully incorporated and expressed in synovial cells within gene-treated joints.

In the clinical study, each patient initially undergoes a medically necessary joint surgery on an affected hand, at which time synovial cells (cells lining the joints) are collected by the researchers. In the laboratory, some of these synovial cells receive a disabled retrovirus containing the gene for IL-Ra. Another batch of cells does not receive the gene. After they have been cultured and have received extensive safety testing, the cells are injected into the four knuckle joints of the patient's previously treated hand. Two of the knuckle joints receive cells carrying the IL1-Ra gene, and the other two knuckle joints receive cells lacking the gene. After one week, the patient receives artificial joint replacements in another medically necessary operation. Knuckles and joint fluid are removed at that time and examined for evidence of gene transfer and expression.

The protocol is designed primarily to test the safety and tolerance of arthritis gene therapy. The introduced gene is not intended to benefit the patient therapeutically. The first patient, a 68-year-old woman treated last July, tolerated the gene transfer and all surgeries well, according to the investigators. Three additional participants have been added to the study, which is expected to recruit a total of nine patients, all of whom are post-menopausal women under age 75.

NOTE TO REPORTERS: For background information, call the UPMC News Bureau representatives listed above or visit the News Bureau WEB site at http://www.upmc.edu.
-end-


University of Pittsburgh Medical Center

Related Rheumatoid Arthritis Articles from Brightsurf:

Reducing dementia in patients with rheumatoid arthritis
The incidence of dementia in patients with rheumatoid arthritis is lower in patients receiving biologic or targeted synthetic disease modifying antirheumatic drugs (DMARDs) than in patients who receive conventional synthetic DMARDs, according to a new study.

Is rheumatoid arthritis two different diseases?
While disease activity improves over time for most rheumatoid arthritis (RA) patients, long-term outcomes only improve in RA patients with autoantibodies, according to a new study published this week in PLOS Medicine by Xanthe Matthijssen of Leiden University Medical Center, Netherlands, and colleagues.

Does the Mediterranean diet protect against rheumatoid arthritis?
Previous research has demonstrated a variety of health benefits associated with the Mediterranean diet, which is rich in olive oil, cereals, fruit and vegetables, fish, and a moderate amount of dairy, meat, and wine.

Reducing corticosteroid use in rheumatoid arthritis
Is the long-term use of glucocorticoids essential in people with chronic inflammatory diseases such as rheumatoid arthritis, or can early discontinuation prevent characteristic side effects?

Rheumatoid arthritis patients under treatment with methotrexate
Patients with rheumatoid arthritis (RA) often suffer from what is referred to as interstitial lung disease (ILD).

Rheumatoid arthritis -- can its onset be delayed or prevented?
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disorder that leads to significant health issues as well as high treatment costs.

Disease burden in osteoarthritis is similar to rheumatoid arthritis
Osteoarthritis (OA) has traditionally been viewed as a highly prevalent but milder condition when compared with rheumatoid arthritis (RA), and some may believe that it is part of a normal aging process requiring acceptance, not treatment.

Prospect of a new treatment for rheumatoid arthritis
An international research group led by Charité -- Universitätsmedizin Berlin has completed testing a new drug to treat rheumatoid arthritis.

Can rare lymphocytes combat rheumatoid arthritis?
Immunologists at Friedrich-Alexander-Universität Erlangen-Nürnberg have demonstrated that ILC2, a group of rare lymphoid cells, play a key role in the development of inflammatory arthritis.

Rheumatoid arthritis meets precision medicine
Scientists are bringing precision medicine to rheumatoid arthritis for the first time by using genetic profiling of joint tissue to see which drugs will work for which patients, reports a new multi-site study.

Read More: Rheumatoid Arthritis News and Rheumatoid Arthritis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.